The United States Patent and Trademark Office recently issued a groundbreaking new patent that addresses one of the most critical public health challenges of our time. Patent No. 12,622,903, titled “Drug products for intranasal administration and uses thereof,” introduces an advanced mechanism for emergency therapeutic delivery. This significant medical advancement was developed and patented by Summit Biosciences Inc., a prominent pharmaceutical company specialized in nasal spray innovations.
The patented invention details a novel drug-device combination product designed for the seamless intranasal delivery of an aqueous pharmaceutical solution. More specifically, the system houses a precise unit dose of an opioid receptor antagonist within a specialized, pre-primed nasal spray device. This configuration ensures that non-medical personnel can rapidly administer a consistent and highly stable dose of a life-saving antidote, such as naloxone, during acute opioid overdose situations where every second counts.
Why the Intranasal Delivery System is Highly Innovative
Traditional methods of administering emergency opioid reversing agents often relied on intramuscular or subcutaneous injections, which require specialized training and carry risks of needle-stick injuries. While early-generation nasal sprays improved accessibility, they frequently suffered from formulation instability, inconsistent droplet size distribution, or complex multi-step activation procedures. Summit Biosciences solved these critical shortcomings by engineering a pre-primed, unit-dose device that guarantees immediate delivery with a single activation. The formulation leverages precise polyol concentrations and advanced chemical stabilizers to enhance the bioavailability of the antagonist across the nasal mucosa. This prevents degradation over a wide temperature range, maximizing the shelf-life and dependability of the medication in real-world emergency environments.
Kentucky State Patent of the Month Recognition for June 2026
Due to its profound public health potential and local economic impact, this invention has been named the Kentucky State Patent of the Month for June 2026. Summit Biosciences is headquartered in Lexington, Kentucky, operating out of the University of Kentucky Coldstream Research Campus. Kentucky and the broader Appalachian region have historically been disproportionately affected by the opioid crisis, making this local scientific breakthrough deeply meaningful. By recognizing this freshly issued patent, the state highlights how Kentucky-based biotechnology firms are leading the global charge against substance abuse. Furthermore, the expansion of Summit Biosciences brings high-paying pharmaceutical manufacturing and research jobs to the state, fortifying Kentucky as an emerging hub for medical device innovation.
U.S. R&D Tax Credit Application and Eligibility
The development and practical application of this intranasal delivery technology represent a classic scenario for securing the U.S. Research and Development (R&D) Tax Credit under Internal Revenue Code Section 41. To qualify, a company must satisfy a four-part test demonstrating that the work was intended to eliminate technical uncertainty, relied on principles of hard science, involved a process of experimentation, and aimed to create a new or improved product function. In this case, the intensive engineering required to formulate a temperature-stable aqueous solution and optimize the mechanical performance of the pre-primed nasal device directly fits these criteria. Eligible expenses would include the wages of the chemical engineers and formulation scientists who developed the composition, the costs of prototype nasal spray devices used in testing, and the expenses associated with rigorous quality control testing. By claiming these credits, pharmaceutical innovators can offset substantial development costs, allowing them to reinvest capital back into life-saving medical discoveries.
